Profusa, Inc. (PFSA) Fair Value 2026

PFSA · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (68/100)

Quick Summary — As of 2026-08-28, Profusa, Inc. (PFSA) trades at $2.93. QOC: 4.1/10. Value Trap Risk: 68/100 (DANGER). 1/13 models active.

Key Facts

Ticker
PFSA
Price
$2.93
Quality Score
4.1/10
Value Trap Risk
68/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 68 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give PFSA?

1 Intrinsic Value Models vs. Current Price ($2.93)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.63 -78.5%

All Models Active

All 1 models are displayed above.

What Is Profusa, Inc. (PFSA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Profusa, Inc.'s intrinsic value is estimated at $0.63. Trading at its current price of $2.93, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -78.5%.

What Do the Models Say About PFSA?

1 of 13 models are currently active for PFSA. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does PFSA Rank in Medical Devices?

Among 159 Medical Devices stocks, PFSA ranks #146 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Profusa, Inc.'s positioning within the Medical Devices segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is PFSA a Value Trap?

CirclFi's Value Trap algorithm assigns PFSA a score of 68/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Profusa, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Profusa, Inc. earns a quality score of 4.1/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PFSA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PFSA's 1 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Profusa, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

NUMDNu-Med Plus, Inc.QOC 4.2MOBIMobia Medical, Inc.QOC 3.9AMIXAutonomix Medical, Inc.QOC 4.2ALMRAlamar Biosciences, Inc.QOC 3.8NVNOenVVeno Medical CorporationQOC 4.2LUDGLudwig Enterprises, Inc.QOC 3.7ITGRInteger Holdings CorporationQOC 8.2QTRXQuanterix CorporationQOC 6.6QTIQT Imaging Holdings, Inc.QOC 5.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: NUMD · MOBI · AMIX · ALMR · NVNO · LUDG · ITGR · QTRX · QTI · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to PFSA?

7 companies across all industries closest to PFSA’s Quality of Company score of 4.1/10.

NGENNervGen Pharma Corp.QOC 4.1BLIVBeLive HoldingsQOC 4.1QNRXQuoin Pharmaceuticals, Ltd.QOC 4.1RDHLRedHill Biopharma Ltd.QOC 4.1TRXAT-REX Acquisition Corp.QOC 4.1PTNPalatin Technologies, Inc.QOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NGEN · BLIV · QNRX · RDHL · TRXA · PTN · NVDA

Where Does PFSA Sit in CirclFi's Medical Devices Rankings?

PFSA is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Profusa, Inc.’s Valuation?

What is Profusa, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Profusa, Inc. (PFSA). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PFSA overvalued or undervalued right now?

At $2.93, 0 of 1 active models suggest PFSA may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Profusa, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.1 mean for PFSA?

Profusa, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PFSA?

CirclFi analyzes PFSA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is PFSA a value trap in 2026?

Profusa, Inc.'s Value Trap score is 68/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Profusa, Inc. (PFSA) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PFSA/ · Methodology
Primary sources for this PFSA valuation
  • Financial statements: Profusa, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001859807) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PFSA as of ; valuations recomputed .